Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-Week Open-Label Extension Study of ACP-204 in Adults with Alzheimer's Disease Psychosis
2023-507351-29-00Phase 3Authorised
- Sponsor
- Acadia Pharmaceuticals
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of remlifanserin in Alzheimer's disease (AD), sponsored by Acadia Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events. Planned start Dec 2024; status: authorised.
02
Drugs
remlifanserin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-507351-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507351-29-00.